Renascience (TSE:4889) Other Current Payables: 円135.87 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4889 Renascience Inc TSE:4889
51 GF Score
Price 円1,148.00
GF Value 円305.40
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Renascience Other Current Payables?

Renascience TSE:4889 -6.67% 51 Other Current Payables is 円135.87 Mil as of Mar. 2026. GuruFocus rates TSE:4889 with a GF Score™ of 51/100 and a GF Value™ of 円305.40 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Renascience's Other Current Payables for the quarter that ended in Mar. 2026 was 円135.87 Mil.

Renascience's quarterly Other Current Payables increased from Sep. 2025 (円64.02 Mil) to Dec. 2025 (円92.27 Mil) and increased from Dec. 2025 (円92.27 Mil) to Mar. 2026 (円135.87 Mil).

Renascience's annual Other Current Payables declined from Mar. 2024 (円114.76 Mil) to Mar. 2025 (円104.65 Mil) but then increased from Mar. 2025 (円104.65 Mil) to Mar. 2026 (円135.87 Mil).

Renascience Other Current Payables Related Terms

Renascience Other Current Payables Historical Data

* Premium members only.

The historical data trend for Renascience's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renascience Other Current Payables Chart

Renascience Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial 20.66 89.01 114.76 104.65 135.87

Renascience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.84 64.02 92.27 135.87 41.51
TSE:4889
51GF Score
Renascience Inc TSE:4889
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renascience Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of 円135.87 Mil mean?
Renascience (TSE:4889) has a Other Current Payables of 円135.87 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Renascience and its competitors.
Is Renascience's Other Current Payables too high?
Renascience's current Other Current Payables is 円135.87 Mil. Overall, Renascience has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Renascience's Other Current Payables compare to ABT and SYK?
Renascience's Other Current Payables of 円135.87 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Devices & Instruments company?
A good Other Current Payables depends on the Medical Devices & Instruments industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Renascience and its competitors. Renascience's current Other Current Payables is 円135.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renascience stock overvalued right now?
Based on GuruFocus' analysis, Renascience (TSE:4889) is currently considered Significantly Overvalued. The stock's GF Value™ is 円305.40, compared to a current price of 円1,148.00 — trading 275.9% above its estimated fair value. The current Other Current Payables is 円135.87 Mil. Renascience's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Renascience (TSE:4889), the current Other Current Payables is 円135.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renascience (TSE:4889) Overvalued in 2026?

Based on GuruFocus' analysis, Renascience stock appears to be overvalued. The current stock price of 円1,148.00 is trading 275.9% above its estimated GF Value™ of 円305.40. GuruFocus considers Renascience to be Significantly Overvalued.

Key valuation signals for TSE:4889:

  • Other Current Payables: 円135.87 Mil
  • GF Value™: 円305.40 vs. price of 円1,148.00 (275.9% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the TSE:4889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renascience Business Description

Address 2-1 Seiryo-cho, Aoba-ku, Miyagi, Sendai, JPN, 103-0023
Renascience Inc is engaged in the Development and commercialization of pharmaceuticals, medical devices, pieces of software as a medical device (SaMD) utilizing AI, etc.
51GF Score

Get the complete analysis for TSE:4889

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,148.00
Price
円305.40
GF Value